Bain Capital Life Sciences | Activity | F4

Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

Team Portfolio Raise Champions Essays

F4/Bain Capital Life Sciences/Activity

Bain Capital Life Sciences Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Investment

Took a minority stake alongside SK Capital Partners in Swixx BioPharma, a rest-of-world pharma commercialization platform.

Swixx Biopharma

Swixx Biopharma Bain Capital Life Sciences

bakermckenzie.comJUN 2026

JUN 2026

Investment

Participated alongside Armistice Capital in a follow-on offering for portfolio company Rapid Micro Biosystems.

Rapid Micro Biosciences

Rapid Micro Biosciences Bain Capital Life Sciences

investors.rapidmicrobio.comMAY 2026

MAY 2026

Milestone

Portfolio company Kailera Therapeutics priced a $625 million IPO, one of biotech's largest-ever public offerings; Bain Capital entities retained roughly 20% ownership.

Kailera Therapeutics

Kailera Therapeutics Bain Capital Life Sciences

biopharmadive.comAPR 17, 2026

APR 17, 2026

Milestone

Portfolio company Beeline Medicines launched to deliver precision therapies for autoimmune and inflammatory disease.

Beeline Medicines

Beeline Medicines Bain Capital Life Sciences

baincapitallifesciences.comAPR 15, 2026

APR 15, 2026

Press

Partner Adam Koppel discussed private equity's growing role in biotech financing.

Adam Koppel on private equity's role in biotech

Bain Capital Life Sciences

biocentury.comJAN 8, 2026

JAN 8, 2026

Milestone

Formed a new company with Bristol Myers Squibb dedicated to developing innovative immunology therapies.

Bristol Myers Squibb and Bain Capital create new immunology company

Bain Capital Life Sciences

baincapitallifesciences.comJUL 28, 2025

JUL 28, 2025

Investment

Led/participated in Atsena Therapeutics' oversubscribed $150 million Series C for ocular gene therapy programs.

Atsena

Atsena Bain Capital Life Sciences

baincapitallifesciences.comAPR 2, 2025

APR 2, 2025

Investment

Acquired a 340-year-old Japanese pharmaceutical company to accelerate Japan drug development.

Tanabe Pharma

Tanabe Pharma Bain Capital Life Sciences

baincapitallifesciences.comFEB 7, 2025

FEB 7, 2025

New Fund

Closed Fund IV with approximately $3 billion of total commitments (~$2.5B from outside LPs).

Fund IV

Bain Capital Life Sciences

baincapital.comSEP 2024

SEP 2024